Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HYPERION CCA: Systemic Therapy +/- Liver-directed RT for Advanced Intrahepatic Cholangiocarcinoma
NCT06858735Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jun 2025
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in intrahepatic cholangiocarcinoma (ICC) comparing Experimental Arm - Liver-RT + Durvalumab with Standard of Care Arm - Durvalumab + Gemcitabine + Cisplatin (2 arms). Primary endpoints: Overall Survival and Safety and Adverse Events. Started Jun 2025; status: recruiting.
02
Drugs
durvalumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06858735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06858735.